Skip to main content
Morphotek's IND for tumor drug accepted for FDA review
1/12/2018

The FDA accepted for review Eisai subsidiary Morphotek's investigational new drug application for MORAb-202, which combines farletuzumab with eribulin to treat patients with solid tumors that express folate receptor alpha.

Full Story: